Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
  • Subscribe
Submit An Article

Latest Articles

  • Monash IVF joins M&A arms race with entry into Perth IVF market via acquisition
    Monash IVF joins M&A arms race with entry into Perth IVF market via acquisition
    • News

  • In an age where celebs own tequila brands, this one owns a hangover cure
    In an age where celebs own tequila brands, this one owns a hangover cure
    • News

  • Markets continue to recover, commodities lead the charge overnight
    Markets continue to recover, commodities lead the charge overnight
    • Market Update

  • Pass go, collect mortgage: Why the Government’s latest first home buyer’s scheme is crap
    Pass go, collect mortgage: Why the Government’s latest first home buyer’s scheme is crap
    • Opinion

  • Crowd Media enters Silicon Valley partnership for interactive NFT collection
    Crowd Media enters Silicon Valley partnership for interactive NFT collection
    • News

  • MPower acquires Lakeland in $8m deal
    MPower acquires Lakeland in $8m deal
    • News

  • US market falls on Tech and Discretionary as Oil surges
    US market falls on Tech and Discretionary as Oil surges
    • Market Update

  • SportsHero launches eSports predictor in China to gamify eSports gambling
    SportsHero launches eSports predictor in China to gamify eSports gambling
    • News

  • This company is offering DNA tests for the whole family, including the dog!
    This company is offering DNA tests for the whole family, including the dog!
    • News

  • Regis Healthcare to claim back $14m spent on aged care COVID outbreaks
    Regis Healthcare to claim back $14m spent on aged care COVID outbreaks
    • News

Osteopore partners with Terumo for collaboration on regenerative bone marrow

  • In News
  • February 1, 2021
  • Alfred Chan
Osteopore partners with Terumo for collaboration on regenerative bone marrow

Medtech company Osteopore (ASX: OSX) will soon have it’s 3D-printed bone regeneration products in the view of major international medical markets through a new collaboration with one of the world’s largest medical companies.

The cross-promotion agreement is with Terumo Blood and Cell Technologies which is wholly owned by Japanese medical conglomerate Terumo (TYO: 4543) which generates more than $8 billion annual revenue.

Between the two parties, respective sales teams will be educated in each others products where Terumo Blood and Cell Technologies’ Autologous Biologics (TAB) technology extracts concentrated bone marrow for bone regeneration while Osteopore’s provides biomimetic scaffolding to guide the bone tissue formation.

Targeted applications of the cross-promoted products include Neurosurgery, Orthopaedics and Reconstructive surgeries and will draw upon Terumo’s extensive network of blood centres, hospitals, therapeutic clinics, researchers, and private medical practices in the Asia-Pacific region.

Further commercial opportunities will be explored by the partnership which would commence with investigator-initiated studies.

For the 12 months ending 31 December 2020, Osteopore reported $1.5 million in sales which represented a 36% increase from the previous year. This was generated primarily through Osteopore’s 3D-printed scaffold tissue that naturally dissolves over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.
Latest posts by Alfred Chan (see all)
  • Monash IVF joins M&A arms race with entry into Perth IVF market via acquisition - May 18, 2022
  • SportsHero launches eSports predictor in China to gamify eSports gambling - May 17, 2022
  • Regis Healthcare to claim back $14m spent on aged care COVID outbreaks - May 16, 2022
  •  
  •  
  •  
  •  
  • autologous biologics
  • medtech
  • orthopaedics
  • Osteopore
  • OSX
  • reconstructive surgery
  • terumo
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.
Latest posts by Alfred Chan (see all)
  • Monash IVF joins M&A arms race with entry into Perth IVF market via acquisition - May 18, 2022
  • SportsHero launches eSports predictor in China to gamify eSports gambling - May 17, 2022
  • Regis Healthcare to claim back $14m spent on aged care COVID outbreaks - May 16, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.
Latest posts by Alfred Chan (see all)
  • Monash IVF joins M&A arms race with entry into Perth IVF market via acquisition - May 18, 2022
  • SportsHero launches eSports predictor in China to gamify eSports gambling - May 17, 2022
  • Regis Healthcare to claim back $14m spent on aged care COVID outbreaks - May 16, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

Copyright © 2020 The Sentiment. All rights reserved.